Search

DexCom Inc

Slēgts

SektorsVeselības aprūpe

91.02 -1.18

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

90.86

Max

92.56

Galvenie mērījumi

By Trading Economics

Ienākumi

50M

249M

Pārdošana

117M

1.3B

P/E

Sektora vidējais

35.083

57.371

EPS

0.7

Peļņas marža

19.039

Darbinieki

11,000

EBITDA

52M

389M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+0.97% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 29. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

5.2B

33B

Iepriekšējā atvēršanas cena

92.2

Iepriekšējā slēgšanas cena

91.02

DexCom Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 21. aug. 19:36 UTC

Social Media

Dexcom Inc shares are higher as $1.6 million in call options signals bullish investor sentiment. The stock has recovered from earlier session lows.

2026. g. 20. aug. 19:36 UTC

Dexcom Inc shares are higher today, continuing a three-session upward trend. The stock has fluctuated within a narrow range during regular trading hours.

2026. g. 19. aug. 19:41 UTC

Dexcom Inc shares are higher Wednesday, pulling back from an early peak. The stock is trading with unusually high volume and remains above its 20-day moving average.

2026. g. 18. aug. 19:16 UTC

Dexcom Inc shares are higher today, reflecting positive market sentiment despite no specific news. The stock remains above its 20-day moving average.

2026. g. 17. aug. 19:46 UTC

Dexcom Inc's shares are lower today, continuing a decline since Friday's close. No specific news has been identified to explain the price movement.

2026. g. 14. aug. 19:16 UTC

Dexcom Inc shares are lower today, continuing a decline since Thursday's close amid broader market caution following an unexpected drop in U.S. retail sales.

2026. g. 13. aug. 19:26 UTC

Dexcom Inc shares are higher today, despite an earlier pullback. The stock's advance contrasts with a broader market decline since the session's start.

2026. g. 12. aug. 19:36 UTC

Dexcom Inc shares are higher amid broader market optimism following inflation data. The core Consumer Price Index showed a modest increase, aligning with forecasts.

2026. g. 11. aug. 23:26 UTC

Dexcom Inc shares are trading lower in after-market hours. Broader market trends and cautious investor sentiment may be influencing this price movement.

2026. g. 10. aug. 20:02 UTC

Dexcom Inc shares are higher today, continuing an upward trend since Friday. The move occurs amid recent labor market data influencing investor sentiment.

2026. g. 7. aug. 23:46 UTC

Dexcom Inc shares are higher in after-market hours, continuing recent positive momentum. The stock remains well above its 20-day moving average.

2026. g. 5. aug. 19:51 UTC

News

Dexcom shares are declining amid negative sentiment in the insulin sector following Podd's revenue growth forecast cut. Broader economic data also influences cautious market sentiment.

2026. g. 4. aug. 19:56 UTC

Dexcom Inc. shares are lower today, pulling back after reaching a session high. The broader market benefits from a significant decline in crude oil prices.

2026. g. 3. aug. 20:02 UTC

News
Social Media

Dexcom Inc. shares are higher following strong Q2 results and raised revenue guidance to $5.22 billion. Canaccord increased its price target to $90.

2026. g. 31. jūl. 20:04 UTC

News
Social Media

Dexcom Inc. shares are higher following analyst upgrades and strong earnings, with second-quarter revenue of $1.31 billion exceeding expectations and guidance raised to $5.22 billion.

2026. g. 30. jūl. 23:51 UTC

News
Social Media

Dexcom reported second-quarter revenue of $1.308 billion and adjusted EPS of $0.70, raising its fiscal year 2026 revenue guidance, with shares trading higher in after-market hours.

2026. g. 29. jūl. 23:41 UTC

Dexcom Inc is trading higher in after-market hours, supported by overall market strength. The asset remains above its 20-day moving average.

2026. g. 28. jūl. 20:06 UTC

News

Dexcom shares rise after UBS initiated coverage with a Buy rating. The stock is advancing since Monday's close of $73.37 amid positive sentiment in the Health Care Equipment sector.

2026. g. 27. jūl. 19:06 UTC

News

Dexcom Inc. gains Health Canada approval for its Dexcom G7 continuous glucose monitoring system, boosting marketability and user adoption amid positive analyst sentiment.

2026. g. 24. jūl. 15:22 UTC

Dexcom Inc's shares are higher today, driven by gains in the Health Care Equipment sub-sector. No specific company news was identified for the movement.

2026. g. 22. jūl. 20:01 UTC

Dexcom Inc. shares are lower today, continuing a decline since Tuesday. Earlier, the stock briefly rose before pulling back.

2026. g. 21. jūl. 19:26 UTC

Dexcom Inc is trading lower, continuing a trend of three consecutive declines. The stock reached a session low earlier today before a slight recovery.

2026. g. 20. jūl. 19:22 UTC

Dexcom Inc shares are lower amid broader market declines and rising Treasury yields. The stock remains near the upper end of its one-month trading range.

Salīdzinājums

Cenas izmaiņa

DexCom Inc Prognoze

Cenas mērķis

By TipRanks

0.97% augšup

Prognoze 12 mēnešiem

Vidējais 93.24 USD  0.97%

Augstākais 105 USD

Zemākais 82 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi DexCom Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

19 ratings

18

Pirkt

1

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
help-icon Live chat